A Multicenter, Open-Label Phase II Study of SyB L-0501 in Patients With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2015
At a glance
- Drugs Bendamustine (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors SymBio Pharmaceuticals
- 12 Nov 2013 Status changed from recruiting to discontinued, according to a SymBio Pharmaceuticals media release.
- 16 May 2013 New source identified and integrated: ClinicalTrials.gov record.
- 26 Dec 2011 The first patient has been enrolled, according to a SymBio Pharmaceuticals media release.